Moleculin Biotech, Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Moleculin Biotech, Inc. (MBRX) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$73.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- Moleculin Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$62.00K, a 2166.67% decline year-over-year.
- Moleculin Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $3.00K.
- Moleculin Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$9.00K.
- Moleculin Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$4.00K, a 133.33% decline year-over-year.
- Moleculin Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $51.00K.
- Moleculin Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$32.00K.
- Moleculin Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$21.00K.
- Moleculin Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$29.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$73.00K 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$62.00K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $51.00K 10-K · filed 2026-03-18 | |||
| 2025-09-30 | -$3.00K 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $3.00K 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | $3.00K 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | -$32.00K 10-K · filed 2026-03-18 | |||
| 2024-09-30 | $13.00K 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$1.00K 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$9.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$21.00K 10-K · filed 2025-03-21 | |||
| 2023-09-30 | -$15.00K 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | -$5.00K 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$4.00K 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | -$29.00K 10-K · filed 2024-03-22 | |||
| 2022-09-30 | -$38.00K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$19.00K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $12.00K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | -$24.00K 10-K · filed 2023-03-22 | |||
| 2021-09-30 | -$26.00K 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$10.00K 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | -$4.00K 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $34.00K 10-K · filed 2022-03-24 | |||
| 2020-09-30 | $2.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$9.00K 10-Q · filed 2021-08-11 | |||
| 2020-03-31 | -$33.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | -$4.00K 10-K · filed 2021-03-24 | |||
| 2019-09-30 | -$16.00K 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$13.00K 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | -$11.00K 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$5.00K 10-K · filed 2020-03-19 | |||
| 2018-09-30 | -$2.00K 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $6.00K 10-Q · filed 2019-08-16 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |